Little Rock, AR – Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will be a Phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users. InterveXion received a positive response to questions submitted to FDA concerning the STAMPOUT protocol with a short list of Division-requested updates or clarifications. All requests were feasible within the current study design and will be addressed in the final protocol. InterveXion has submitted an NIH grant application to fund this proof-of-concept study and hopes to begin in Q1-2018.
Recent Posts
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
- InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
- InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
- InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder
Archives
- October 2021
- September 2021
- April 2021
- October 2020
- May 2020
- February 2020
- January 2020
- December 2019
- November 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- January 2019
- December 2018
- November 2018
- May 2018
- January 2018
- October 2017
- June 2017
- January 2016
- January 2015
- November 2014
- February 2014
- August 2013
- July 2013
- December 2012
- November 2012
- May 2012
- April 2012
- July 2011
- April 2011
- October 2009
- September 2009
- March 2005
- January 2005
Recent Comments